<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00527410</url>
  </required_header>
  <id_info>
    <org_study_id>RTA 744-C-0601</org_study_id>
    <nct_id>NCT00527410</nct_id>
  </id_info>
  <brief_title>A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis</brief_title>
  <acronym>LMD</acronym>
  <official_title>A Phase I Safety and Pharmacokinetic Study of Intravenous RTA 744 Injection in Patients With Recurrent, Progressive or Refractory Neoplastic Meningitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reata Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reata Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assesses the tolerability, safety, efficacy and pharmacokinetics of RTA 744 in&#xD;
      recurrent neoplastic meningitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neoplastic meningitis refers to the deposition of malignant cells in the lining&#xD;
      (leptomeninges) of the brain and spine. Neoplastic meningitis from solid tumors most often&#xD;
      occurs in patients with advanced systemic disease who have failed prior chemotherapy; it is&#xD;
      also frequent in patients with CNS parenchymal metastasis. Patient survival remains low, and&#xD;
      better treatments are needed to penetrate the blood brain barrier and treat the entire&#xD;
      neuraxis.&#xD;
&#xD;
      RTA 744 is a close chemical analogue of the well characterized anti-cancer agent doxorubicin.&#xD;
      Unlike doxorubicin, RTA 744 has shown ability to cross the blood brain barrier and to achieve&#xD;
      high concentration in CNS tumor tissue in animal models. Dose escalation will continue as&#xD;
      pre-determined until first occurrence of a dose-limiting toxicity. Maximum tolerated dose&#xD;
      will be determined as defined in protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business Decision&#xD;
  </why_stopped>
  <start_date>October 2006</start_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the tolerability of RTA 744 Injection in patients with leptomeningeal disease (LMD) secondary to any type of primary tumor.</measure>
    <time_frame>evaluation at end of cycle 1 for each cohort</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize the multiple-dose pharmacokinetics of RTA 744 in plasma and CSF in a selected group of 6-10 patients who will receive RTA 744 at or near the maximum tolerated dose (MTD).</measure>
    <time_frame>end of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Document any potential antitumor activity.</measure>
    <time_frame>after every even numbered treatment cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlate pharmacokinetic information with clinical (efficacy and safety) responses.</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Leptomeningeal Carcinomatosis</condition>
  <arm_group>
    <arm_group_label>RTA 744</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RTA 744 injection administered intravenously for a maximum of 18 cycles (54 weeks). Dose escalation based on four dose levels and occurance of dose limiting toxicity (DLT).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RTA 744</intervention_name>
    <description>Aqueous solution of RTA 744 is packaged in 5 ml vials - 1 mg/ ml. The drug is mixed in D10W and infused over 2 hours on three consecutive days.</description>
    <arm_group_label>RTA 744</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic confirmation of primary malignancy. All primary tumor types may be&#xD;
             enrolled.&#xD;
&#xD;
          -  Neoplastic meningitis/leptomeningeal metastasis refractory to conventional therapy&#xD;
             with presence of tumor cells on cytology, OR neuroimaging evidence of leptomeningeal&#xD;
             tumor by MRI.&#xD;
&#xD;
          -  Not eligible for higher priority clinical trial.&#xD;
&#xD;
          -  Have recovered from side effects of any surgical resection.&#xD;
&#xD;
          -  A stable dose of steroid for at least 7 days prior to the Gd-MRI.&#xD;
&#xD;
          -  Karnofsky Performance Status (KPS) of ≥ 60.&#xD;
&#xD;
          -  Laboratory Parameters: ANC ≥ 1.5 x 109/L; Hgb ≥ 9 g/dl; Platelets ≥ 100 x 109/L; AST&#xD;
             and ALT ≤ 3.0 x ULN; Serum bilirubin ≤ 1.5 x ULN; Serum creatinine ≤ 1.5 x ULN; 24&#xD;
             hour creatinine clearance ≥ 50 ml/min&#xD;
&#xD;
          -  Life expectancy of at least 8 weeks.&#xD;
&#xD;
          -  Written informed consent obtained.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent therapy for leptomeningeal disease or other malignancy.&#xD;
&#xD;
          -  Clinical evidence of obstructive hydrocephalus or compartmentalization of CSF flow.&#xD;
&#xD;
          -  Cumulative doses: doxorubicin &gt; 450 - 550 mg/m2, epirubicin &gt; 800-1000 mg/m2,&#xD;
             idarubicin &gt;130-150 mg/m2 and daunorubicin &gt; 400-550 mg/m2.&#xD;
&#xD;
          -  Anticonvulsant medications or other types of medications which are known to induce the&#xD;
             CYP450 enzymes.&#xD;
&#xD;
          -  Pregnancy or breast feeding, or adults (male or female) of reproductive potential not&#xD;
             employing an effective method of birth control&#xD;
&#xD;
          -  Total 24 hour urinary protein &gt; 500 mg.&#xD;
&#xD;
          -  Concurrent severe and/or uncontrolled medical conditions which could compromise&#xD;
             participation in the study&#xD;
&#xD;
          -  Impaired cardiac function, other significant prior cardiac disease or arrhythmia of&#xD;
             any type&#xD;
&#xD;
          -  Myocardial infarction ≤ 6 months prior&#xD;
&#xD;
          -  History of CHF or arrhythmias&#xD;
&#xD;
          -  Therapeutic doses of anticoagulant therapy (prophylactic dosing is allowed)&#xD;
&#xD;
          -  Investigational drugs less than 4 weeks prior; intrathecal chemotherapy within 2 weeks&#xD;
             prior; systemic cytotoxic chemotherapy within 4 weeks prior (6 weeks for nitrosourea&#xD;
             or mitomycin-C or 2 weeks for vincristine); radiation therapy within 2 weeks prior;&#xD;
             any medication known to cause QT interval prolongation&#xD;
&#xD;
          -  Any surgery &lt;2 weeks prior&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>September 7, 2007</study_first_submitted>
  <study_first_submitted_qc>September 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2007</study_first_posted>
  <last_update_submitted>November 12, 2014</last_update_submitted>
  <last_update_submitted_qc>November 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Meningeal Carcinomatosis</mesh_term>
    <mesh_term>Meningitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

